Cost implications of early treatment discontinuation in cancer: a real-world data analysis

Approximately 30% of anticancer treatments are discontinued early, accounting for nearly 10% of medicine costs. While ETD highlights opportunities to improve efficiency, it also includes clinically justified and unavoidable discontinuations. Efforts to reduce avoidable ETD through improved patient selection, toxicity prediction, and treatment optimization are essential for more rational and equitable use of high-cost anticancer therapies.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-02-24
DOI
https://doi.org/10.1093/oncolo/oyaf436
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost implications of early treatment discontinuation in cancer: a real-world data analysis

H W M van Laarhoven, G W J Frederix, M H Delsing, T Schutte et al.
The Oncologist
Economic and Financial Impacts of Cancer
article

Cost implications of early treatment discontinuation in cancer: a real-world data analysis

H W M van Laarhoven, G W J Frederix, M H Delsing, T Schutte, L Timmers, H C Post, C E M Hollak, K Opmeer
article en

Abstract

Approximately 30% of anticancer treatments are discontinued early, accounting for nearly 10% of medicine costs. While ETD highlights opportunities to improve efficiency, it also includes clinically justified and unavoidable discontinuations. Efforts to reduce avoidable ETD through improved patient selection, toxicity prediction, and treatment optimization are essential for more rational and equitable use of high-cost anticancer therapies.

The OncologistVol. 31(4)
University Medical Center Utrecht (NL), National Health Care Institute (NL), Amsterdam Neuroscience (NL), Oncode Institute (NL), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL), Zorginstituut Nederland (NL), Royal Dutch Society for the Promotion of Dentistry (NL), Amsterdam University Medical Centers (NL), Cancer Center Amsterdam (NL), Vrije Universiteit Amsterdam (NL), University of Amsterdam (NL), Erasmus University Rotterdam (NL)
Good health and well-being
Openalex Percentile: Top 46%
Economic and Financial Impacts of Cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.